Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC

KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of epidermal growth factor receptor inhibitor (EGFRI) resistance. There are currently no targeted therapies approved specifically for the treatment of KRAS-active non–small cell lung cancers (NSCLC). Atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Gober, Madeline Krentz, Flight, Robert M, Lambert, Joshua, Moseley, Hunter, Stromberg, Arnold, Black, Esther P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509975/
https://www.ncbi.nlm.nih.gov/pubmed/31105425
http://dx.doi.org/10.1177/1176935119843507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509975/
https://www.ncbi.nlm.nih.gov/pubmed/31105425
http://dx.doi.org/10.1177/1176935119843507

Ejemplares similares